Las Vegas Nevada Clinical Trials

Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
The purpose of this study is to evaluate the safety and efficacy of various fixed daily doses of WC3055 compared with placebo for the treatment of subjects with LUTS secondary to BPH.
Status: Recruiting Start Date: August 2013 Completion Date: September 2014
A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
A randomized study evaluating the safety and efficacy of elagolix in the management of moderate to severe endometriosis-associated pain in adult premenopausal female subjects.
Status: Recruiting Start Date: September 2013 Completion Date: April 2016
Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
The primary purpose of this study is to compare the objective response rate (ORR) as determined by investigators, of Nivolumab combined with Ipilimumab versus Ipilimumab monotherapy in subjects with unresectable or metastatic melanoma
Status: Recruiting Start Date: August 2013 Completion Date: May 2015
Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets
This is a 6-month, nonrandomized, open-label extension study to assess the long-term safety of hydrocodone bitartrate extended-release tablets in patients with moderate to severe chronic low back pain who require continuous opioid treatment for an extended period of time.
Status: Recruiting Start Date: July 2013 Completion Date: August 2014
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
The goal of this study is to test a new vitamin D compound for its ability to reduce parathyroid hormone levels in patients who are on hemodialysis.
Status: Recruiting Start Date: September 2013 Completion Date: October 2014
A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)
This study is designed to demonstrate the non-inferior antiviral activity of DTG/ABC/3TC fixed dose combination (FDC) once daily (OD) compared to atazanavir plus ritonavir (ATV+RTV) and tenofovir disoproxil fumarate/emtricitabine fixed dose combination (TDF/FTC FDC) OD in HIV-1 infected, ART-naïve [more...]  women over 48 weeks. This study will also characterize the safety and tolerability of DTG/ABC/3TC FDC compared to ATV+RTV+TDF/FTC FDC. Sufficient number of subjects will be screened in order to ensure a total of approximately 474 subjects will be randomized (237 in each study arm)
Status: Recruiting Start Date: August 2013 Completion Date: March 2018
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with placebo on overall survival in subjects with advanced hepatocellular carcinoma who have received prior sorafenib.
Status: Recruiting Start Date: August 2013 Completion Date: 
Pediatric Autism Study
This is a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of 2 fixed doses of lurasidone (20 mg/day and 60 mg/day) for 6 weeks compared with placebo in pediatric and adolescent subjects with irritability associated with [more...]  autistic disorder who reside in the community setting.
Status: Recruiting Start Date: August 2013 Completion Date: September 2015
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
The purpose of this study is to evaluate the hemoglobin response (efficacy), safety, and tolerability of orally administered AKB-6548 in patients with Chronic Kidney Disease (pre-dialysis) with anemia with dosing for 20 weeks.
Status: Recruiting Start Date: July 2013 Completion Date: November 2014
A Study of MPDL3280A Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Platinum Failure
This multicenter, open-label, randomized study will evaluate the efficacy and safety of MPDL3280A compared with docetaxel in patients with advanced or metastatic non-small cell lung cancer after platinum failure. Patients will be randomized to receive either MPDL3280A 1200 mg [more...]  intravenously every 3 weeks or docetaxel 75 mg/m2 intravenously every 3 weeks. Treatment may be continued for a maximum of 16 cycles (or 12 months, whichever occurs first) in the absence of disease progression or unacceptable toxicity.
Status: Recruiting Start Date: September 2013 Completion Date: March 2017
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
To test the idea that solanezumab will slow the cognitive and functional decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD.
Status: Recruiting Start Date: July 2013 Completion Date: December 2016
An Observational Study in Patients With Asthma Initiating Treatment With Xolair (Omalizumab)
This observational study will evaluate the correlation of patient's characteristics with predictive markers of clinical outcome in patient with moderate to severe asthma initiating treatment with Xolair (omalizumab). Data will be collected for 48 weeks.
Status: Recruiting Start Date: June 2013 Completion Date: November 2015
Phase I/II, Single Center, Single-Treatment, Open-Label, Adaptive Clinical Trial Design Examining Pk of Two MR Formulations of MPH in Adolescent/Pediatric Subjects With ADHD
This study will be conducted in 2 separate stages, the first in adolescents and the second in children. Both Stages 1 and 2 will use an adaptive, single or multiple cohort open-label, single-treatment, fasting design examining the pharmacokinetic (PK) effects of up to 2 [more...]  separate modified release formulations (B and C) of HLD200 (54 mg).
Status: Recruiting Start Date: August 2013 Completion Date: October 2013
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
The purpose of this study is to evaluate the safety and efficacy of CB-5945 for the treatment of opioid-induced constipation (OIC)in adults taking opioid therapy for chronic non-cancer pain.
Status: Recruiting Start Date: June 2013 Completion Date: August 2015
The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
The purpose of this study is to evaluate the safety and efficacy of CB-5945 for the treatment of opioid-induced constipation (OIC)in adults taking opioid therapy for chronic non-cancer pain.
Status: Recruiting Start Date: June 2013 Completion Date: August 2015
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
The purpose of this study is to determine whether the investigational drug SelG1 when given to sickle cell disease patients either taking or not taking hydroxyurea is effective in preventing or reducing the occurrence of pain crises. SelG1 prevents various cells in the [more...]  bloodstream from sticking together. By stopping these cell-cell interactions, SelG1 may prevent small blood vessels from becoming blocked and therefore reduce the occurrence and severity of pain crises. Other effects of SelG1 will also be evaluated, as well as the safety of the drug and how long it stays in the blood stream.
Status: Recruiting Start Date: July 2013 Completion Date: 
An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis
The purpose of this study is to investigate the long-term safety and any side effects of baricitinib in participants who have completed a previous baricitinib rheumatoid arthritis study. The study provides for 2 years of additional treatment with baricitinib, [more...]  but may be extended to allow for continued treatment for up to 5 years after evaluation of the safety profile of baricitinib.
Status: Recruiting Start Date: June 2013 Completion Date: June 2020
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
The purpose of this study is to evaluate the efficacy, safety and tolerability of ISIS-GCGRRx in combination with metformin versus placebo + metformin
Status: Recruiting Start Date: July 2013 Completion Date: February 2015
AR08 for Treatment of ADHD in Children
This is a multicenter, multiple dose, randomized, double-blind, placebo-controlled, forced titration study. Patients will be randomized to 1 of 4 treatment groups in a 1:1:1:1 ratio. One-hundred twenty (120) patients are planned to be randomized. Each patient will receive [more...]  AR08 (0.5, 1, or 2 mg per day) or matching placebo for seven (7) weeks.
Status: Recruiting Start Date: June 2013 Completion Date: 
A Study of Lebrikizumab in Patients With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication
This randomized, multicenter, double-blind, placebo-controlled. parallel-group study will evaluate the efficacy and safety of lebrikizumab in patients with asthma whose disease remains uncontrolled despite daily treatment with inhaled corticosteroid therapy and at least one second controller medication. Patients will [more...]  be randomized 1:1:1 to receive double-blind treatment with either lebrikizumab ("high" or "low") or placebo, administered subcutaneously every 4 weeks for 52 weeks, in addition to their standard-of-care therapy. This will be followed by a 52-week double-blind active treatment extension. The anticipated time on study treatment is 104 weeks. After study treatment, all patients will complete a 20 week safety follow-up.
Status: Recruiting Start Date: July 2013 Completion Date: September 2017
A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
This randomized, multicenter, double-blind, placebo-controlled. parallel-group study will evaluate the efficacy and safety of lebrikizumab in patients with asthma whose disease remains uncontrolled despite daily treatment with inhaled corticosteroid therapy and at least one second controller medication. Patients will [more...]  be randomized 1:1:1 to receive double-blind treatment with either lebrikizumab ("high" or "low") or placebo, administered subcutaneously every 4 weeks for 52 weeks, in addition to their standard-of-care therapy. This will be followed by a 52-week double-blind active treatment extension. The anticipated time on study treatment is 104 weeks. After study treatment, all patients will complete a 20 week safety follow-up.
Status: Recruiting Start Date: July 2013 Completion Date: September 2017
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 1)
The overall objective of this study is to assess the efficacy and safety of treatment with PT003 (GFF MDI), PT005 (FF MDI), PT001 (GP MDI), and open-label tiotropium bromide inhalation powder compared with each other and Placebo MDI over 24 weeks in subjects with [more...]  moderate to very severe COPD.
Status: Recruiting Start Date: May 2013 Completion Date: 
Open Label Study of Long Term Evaluation Against LDL-C Trial-2
This study will contribute to the evaluation of long-term safety, tolerability and efficacy of AMG 145 in subjects with hyperlipidemia and subjects with mixed dyslipidemia.
Status: Recruiting Start Date: April 2013 Completion Date: January 2017
Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy.
Status: Recruiting Start Date: August 2013 Completion Date: January 2022
[1] 2 3 4 Next >>

 

Clinical trials allow volunteers access to medical treatment options before they are available to the general public. Participants often receive the best healthcare available for their condition.

Risks are a reality, however, and may include more frequent doctor visits, health risks (possibly life-threatening), and/or the treatment being ineffective. Trials are federally regulated with strict guidelines to protect participants.

Las Vegas Nevada Clinical Trials Information presented on ClinicalTrialsSearch.org is not intended to be a substitute for qualified medical advice visit or treatment with a real physician. We are not physicians. Always consult with a medical doctor (MD). ClinicalTrialsSearch.org is a website dedicated to listing clinical research studies in human subjects, including those specifically related to Las Vegas Nevada. Clinical research trials and medical trials take place in hundreds of cities across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectiveness of new treatments and drugs. The purpose of the studies is to answer specific human health questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions. Clinical trials allow volunteers access to medical treatment options before they are available to the general public. Many times the participants receive treatment for free, and sometimes they are paid for their time. Participants often receive the best healthcare available possible for their condition. Risks are a reality, however, and may include more frequent doctor visits, health risks (possibly life-threatening), and/or the treatment being ineffective. U.S. - based Las Vegas Nevada studies are federally regulated with strict guidelines to protect patients.

Latest Clinical
Trials News
Diabetes Clinical Trials search for new treatments and cures
03/14/2010

There are a number of clinical trials underway to find effective treatments for diabetes, including new drugs, surgery and even transplantation.

Feeling Depressed? A clinical trial might help.
03/07/2010

There are several current and ongoing trials of interventions for major depressive disorder, which is characterized by a disabling combination of symptoms causing severe disruption to the sufferer's ability to carry out routine functions and tasks of daily life.

The State of Constipation Clinical Trials
02/28/2010

Constipation is a illness where the bowels cannot move waste material out of the body in a normal manner. There are various clinical trials recruiting participants to study the effectiveness of various treatments.

view more...